Traders should monitor upcoming data readouts in late 2026 when the extension study completes. The durable signal and dual biomarker response may prompt increased analyst interest and potential partnership discussions, especially given the novel mechanism in a high-unmet-need area.
Price Chart
Executive Summary
Gain Therapeutics presented new Phase 1b clinical data for GT-02287 in Parkinson’s disease at AD/PD 2026, showing biomarker improvements (reduced CSF GluSph and DDC) and stable MDS-UPDRS scores over 150 days. The company also unveiled a new preclinical chemical series led by GT-04686, ready for IND-enabling studies. These results support GT-02287's potential as a disease-modifying therapy in both idiopathic and GBA1-associated PD.
Key Facts
- GT-02287 demonstrated reduction in CSF glucosylsphingosine (GluSph) and DOPA decarboxylase (DDC), two emerging PD biomarkers, after 90 days of dosing
- MDS-UPDRS scores remained stable over 150 days of treatment, with a 6.7-point difference favoring high baseline GluSph patients
- 16 of 19 participants chose to continue into the 9-month extension study, supporting drug tolerability
- Data Monitoring Committee confirmed continuation of the study without changes as of March 5, 2026
- New preclinical series led by GT-04686 is ready for IND-enabling studies, expanding pipeline beyond GT-02287
Financial Impact
Non-dilutive value inflection: biomarker and clinical durability data de-risk Phase 1b program and support future trial design; no immediate revenue impact but increases probability of success
Risk Factors
- Phase 1b is open-label and small (n=19), limiting statistical power
- MDS-UPDRS stability is encouraging but not equivalent to improvement; larger controlled trials needed
- GT-04686 remains preclinical with no human safety or efficacy data yet
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258138 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | Press Release | $1.72 $1.62 | ▼ −6.10% | ▼ −7.41% | $1.18 (−31.10%) |
Oct 1, 2026 26d ago | 8-K | $1.72 $1.62 | ▼ −6.10% | ▼ −7.41% | $1.18 (−31.10%) |
Aug 11, 2026 11w ago | Press Release | $2.06 $2.03 | ▼ −1.46% | ▼ −1.05% | $1.18 (−42.48%) |
Jul 16, 2026 14w ago | 8-K | $1.66 $1.82 | ▲ +9.64% | ▲ +11.31% | $1.18 (−28.61%) |
Jun 29, 2026 17w ago | 8-K | $2.03 $1.81 | ▼ −10.84% | ▼ −11.44% | $1.18 (−41.63%) |
Jun 29, 2026 17w ago | Press Release | $2.03 $1.81 | ▼ −10.84% | ▼ −11.44% | $1.18 (−41.63%) |
May 26, 2026 22w ago | 8-K | $1.82 $1.96 | ▲ +7.69% | ▲ +6.61% | $1.18 (−34.89%) |
May 11, 2026 24w ago | Press Release | $1.82 $1.62 | ▼ −10.99% | ▼ −10.90% | $1.18 (−34.89%) |
Apr 28, 2026 25w ago | DEFA14A | $1.76 $1.91 | ▲ +8.52% | ▲ +5.41% | $1.18 (−32.67%) |
Mar 26, 2026 30w ago | Press Release | $1.89 $1.85 | ▼ −2.12% | ▼ −3.75% | $1.18 (−37.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers